Albendazole 400mg tablets
Requires a prescription from a doctor or prescriber
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Albendazole
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Albendazole
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
400 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 16 · Randomised trials: 29 · 2011–2026
Showing the 50 most relevant studies, sorted by most relevant.
M. Palmeirim, Eveline Hürlimann, S. Knopp, et al.
PLoS Neglected Tropical Diseases, 2018
Cesar Henriquez-Camacho, E. Gotuzzo, J. Echevarría, et al.
The Cochrane Database of Systematic Reviews, 2016
Hector H. Garcia, I. Gonzales, Andres G. Lescano, et al.
The Lancet. Infectious diseases, 2014
Jorge Pitanga, Murilo Cruccioli, Pedro Teixeira, et al.
Neurology, 2025
Muhammad Farhan, Syed Moiz Abbas, Areeba Khan, et al.
Acta Tropica, 2025
Resende Gondim Jasmineiro Pitanga J, Marmori Cruccioli M, Carneiro PHT, et al.
2026
Luísa Menegaz, Gabriela Oliveira Caetano, Jade Lingiardi Altoé, et al.
2024
Abstract Neurocysticercosis is a parasitic neurological disease, considered by the World Health Organization (WHO) as one of the most neglected tropical diseases in the world, also being an important public health concern in Brazil. The eggs of the Taenia solium hatch and the larvae spread through highly vascularized tissues, including the brain. Most patients are asymptomatic, but in some cases, cysts can cause inflammation, which can lead to headaches, seizures, and intracranial hypertension. The preferred treatment for neurocysticercosis remains unclear: the combination therapy of albendazole plus praziquantel has been associated with greater benefits than albendazole alone.
Abstract licence: CC BY 4.0
Resende Gondim Jasmineiro Pitanga J, Marmori Cruccioli M, Carneiro PHT, et al.
2026
Bing-Cheng Zhao, Hong-ye Jiang, Wei-Ying Ma, et al.
PLoS Neglected Tropical Diseases, 2016
happy modi, arya patel, mitul makwana, et al.
Journal of Advanced Pharmacy Research, 2025
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
8 to 12 hours
Mechanism
Albendazole causes degenerative alterations in the tegument and intestinal cells…
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
8 to 12 hours
Protein binding
70%
Metabolism
Elimination
1%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 748 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC P02CA03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Albendazole
Additional database identifiers
Drugs Product Database (DPD)
1263
ChemSpider
1998
BindingDB
50241293
PDB
ALW
ZINC
ZINC000017146904
UniProt Accession
F1L7U3_ASCSU
HUGO Gene Nomenclature Committee (HGNC)
HGNC:20766
GenAtlas
TUBA1A
GeneCards
TUBA1A
GenBank Gene Database
X01703
GenBank Protein Database
37492
UniProt Accession
TBA1A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:20771
GenAtlas
TUBB2C
GeneCards
TUBB4B
GenBank Gene Database
X02344
GenBank Protein Database
37494
UniProt Accession
TBB4B_HUMAN
GenBank Gene Database
AE014299
GenBank Protein Database
24346572
UniProt Accession
FCCA_SHEON
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2595
GeneCards
CYP1A1
GenBank Gene Database
K03191
GenBank Protein Database
181276
Guide to Pharmacology
1318
UniProt Accession
CP1A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2621
GeneCards
CYP2C19
GenBank Gene Database
M61854
GenBank Protein Database
181344
Guide to Pharmacology
1328
UniProt Accession
CP2CJ_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q411629), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.